专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10512600B2 RNA complexes that inhibit melanin production 有权
公开(公告)号：US10512600B2
公开(公告)日：2019-12-24
申请号：US16102155
申请日：2018-08-13
申请人： OliX Pharmaceuticals, Inc.
发明人： Sun Woo Hong , Isu Hong , Ji Hyun Kim
IPC分类号： A61K8/60 , A61K31/713 , C12N15/113 , A61Q19/02 , A61Q19/08 , A61K45/06
摘要： In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs and lasiRNAs) that inhibit tyrosinase expression and are therefore useful for reducing melanin production and for treating pigmentation-related disorders associated with excessive melanin production, such as melasma and age spots.

2. 发明授权

US10064801B2 RNA complexes that inhibit melanin production 有权
公开(公告)号：US10064801B2
公开(公告)日：2018-09-04
申请号：US15220767
申请日：2016-07-27
申请人： OliX Pharmaceuticals, Inc.
发明人： Sun Woo Hong , Isu Hong , Ji Hyun Kim
IPC分类号： A61K31/713 , A61K8/60 , A61Q19/02 , C12N15/113 , A61K45/06 , A61Q19/08
摘要： In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs and lasiRNAs) that inhibit tyrosinase expression and are therefore useful for reducing melanin production and for treating pigmentation-related disorders associated with excessive melanin production, such as melasma and age spots.

3. 发明授权

US10301628B2 Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor 有权
公开(公告)号：US10301628B2
公开(公告)日：2019-05-28
申请号：US15483305
申请日：2017-04-10
申请人： OliX Pharmaceuticals, Inc.
发明人： Dong Ki Lee , Sun Woo Hong , Tae Yeon Lee , Sae-Lo-Oom Lee , Ji Hyun Kim , Yu Ran Na , Young-Dong Kim
IPC分类号： C12N15/113 , A61K9/00
摘要： In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit CTGF expression and are therefore useful for treating idiopathic pulmonary fibrosis.

4. 发明授权

US10125362B2 RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor 有权
公开(公告)号：US10125362B2
公开(公告)日：2018-11-13
申请号：US14403121
申请日：2013-05-21
申请人： OliX Pharmaceuticals, Inc.
发明人： Sun Woo Hong
IPC分类号： C12N15/11 , C12N15/113 , C12N15/87
摘要： Provided herein are RNAi-inducing double-stranded nucleic acid molecules having cell penetrating ability and targeting mRNA encoding a connective tissue growth factor (CTGF). In certain embodiments, the RNAi-inducing double-stranded nucleic acid molecule comprises a first strand of having a sequence of UCUUCCAGUCGGUAAGCCGCGAGGGCAGGCC and comprising 4 to 17 phosphorothioate bonds and at least one 2′-O-Me modified nucleotide, as well as a second strand having a sequence of CUUACCGACUGGAAGA and comprising at least one phosphorothioate bond and at least one 2′-O-Me modified nucleotide and further comprising a cholesterol moiety covalently attached to its 3′ end.

5. 发明授权

US10883105B2 RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor 有权
公开(公告)号：US10883105B2
公开(公告)日：2021-01-05
申请号：US16135766
申请日：2018-09-19
申请人： OliX Pharmaceuticals, Inc.
发明人： Sun Woo Hong
IPC分类号： C12N15/11 , C12N15/113 , C12N15/87
摘要： The present invention relates to a novel, RNAi-inducing nucleic acid molecule having cell penetrating ability and the use thereof, and more particularly, to a novel, RNAi-inducing double-stranded nucleic acid molecule, which has a replacement of the phosphate backbone of at least one nucleotide with phosphorothioate or phosphorodithioate, and has a lipophilic compound conjugated thereto, and thus has high target gene-silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle, and to a method of silencing a target gene using the nucleic acid molecule. The nucleic acid structure according to the present invention has both cholesterol modification and phosphorothioate modification introduced therein, and thus has high gene silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle. Thus, it can be delivered into an actual target area in an amount sufficient for induction of RNAi, and thus can overcome the in vivo delivery problem occurring in the prior art. Therefore, the nucleic acid molecule according to the invention can effectively substitute for conventional siRNA molecules to treat cancer or viral infections.

6. 发明授权

US10519449B2 Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB 有权
公开(公告)号：US10519449B2
公开(公告)日：2019-12-31
申请号：US15422122
申请日：2017-02-01
申请人： OliX Pharmaceuticals, Inc.
发明人： Dong Ki Lee , Sun Woo Hong , Tae Yeon Lee , Sae-Lo-Oom Lee , Hanna Lee , Dayeon Yu , Ji Eom
IPC分类号： C12N15/113 , A61K31/713 , A61K45/06
摘要： In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit ANGPT2 and/or PDGFB expression and are therefore useful for treating angiogenesis-associated diseases, such as cancer, AMD, and DME.

7. 发明授权

US10059949B2 Treatment of age-related macular degeneration using RNA complexes that target MYD88 or TLR3 有权
公开(公告)号：US10059949B2
公开(公告)日：2018-08-28
申请号：US15352322
申请日：2016-11-15
申请人： OliX Pharmaceuticals, Inc.
发明人： Dong Ki Lee , Sun Woo Hong , Isu Hong , Jihye Hwang
IPC分类号： C12N15/113
CPC分类号： C12N15/1138 , C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2320/32 , C12N2310/3521
摘要： In certain aspects, provided herein are RNA complexes that inhibit Myeloid differentiation primary response gene 88 (MyD88) and/or Toll-like receptor 3 (TLR3) and are useful in the treatment of age-related macular degeneration (AMD). In certain aspects, provided herein are pharmaceutical compositions comprising such RNA complexes and methods of using such RNA complexes and pharmaceutical compositions.

8. 发明申请

US20170137828A1 TREATMENT OF AGE-RELATED MACULAR DEGENERATION USING RNA COMPLEXES THAT TARGET MYD88 OR TLR3 审中-公开
公开(公告)号：US20170137828A1
公开(公告)日：2017-05-18
申请号：US15352322
申请日：2016-11-15
申请人： OliX Pharmaceuticals, Inc.
发明人： Dong Ki Lee , Sun Woo Hong , Isu Hong , Jihye Hwang
IPC分类号： C12N15/113
CPC分类号： C12N15/1138 , C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2320/32 , C12N2310/3521
摘要： In certain aspects, provided herein are RNA complexes that inhibit Myeloid differentiation primary response gene 88 (MyD88) and/or Toll-like receptor 3 (TLR3) and are useful in the treatment of age-related macular degeneration (AMD). In certain aspects, provided herein are pharmaceutical compositions comprising such RNA complexes and methods of using such RNA complexes and pharmaceutical compositions.

9. 发明授权

US10829761B2 Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor 有权
公开(公告)号：US10829761B2
公开(公告)日：2020-11-10
申请号：US16380638
申请日：2019-04-10
申请人： OliX Pharmaceuticals, Inc.
发明人： Dong Ki Lee , Sun Woo Hong , Tae Yeon Lee , Sae Lo Oom Lee , Ji Hyun Kim , Yu Ran Na , Young-Dong Kim
IPC分类号： C12N15/113 , A61K9/00
摘要： In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit CTGF expression and are therefore useful for treating idiopathic pulmonary fibrosis.

10. 发明授权

US10590423B2 Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3 有权
公开(公告)号：US10590423B2
公开(公告)日：2020-03-17
申请号：US16042833
申请日：2018-07-23
申请人： OliX Pharmaceuticals, Inc.
发明人： Dong-ki Lee , Sun Woo Hong , Isu Hong , Jihye Hwang
IPC分类号： C12N15/113
摘要： In certain aspects, provided herein are RNA complexes that inhibit Myeloid differentiation primary response gene 88 (MyD88) and/or Toll-like receptor 3 (TLR3) and are useful in the treatment of age-related macular degeneration (AMD). In certain aspects, provided herein are pharmaceutical compositions comprising such RNA complexes and methods of using such RNA complexes and pharmaceutical compositions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式